Signal detection and analysis of adverse events associated with Genvoya® based the FAERS database
2024

Safety Profile of Genvoya® Analyzed Through FAERS Database

Sample size: 2376 publication Evidence: moderate

Author Information

Author(s): Wang Chengliang, Zhang Yan, Tang Xiting, Zhang Guoping, Chen Li

Primary Institution: People’s Hospital of Ganzi Tibetan Autonomous Prefecture, Kangding, Sichuan, China

Hypothesis

This study aims to evaluate and understand the safety profile of Genvoya® by analyzing adverse drug event reports from the FAERS database.

Conclusion

Multiple adverse reactions were observed with the use of Genvoya®, highlighting the need for clinicians to monitor these reactions closely.

Supporting Evidence

  • Common adverse events included weight gain, drug interactions, and increased viral load.
  • New potential adverse reactions such as fat redistribution and HIV-associated neurocognitive disorders were identified.
  • Reports from male patients accounted for 74.33% of the total adverse event reports.

Takeaway

This study looked at reports of problems people had while taking Genvoya®, a medicine for HIV, and found that it can cause several side effects that doctors need to watch out for.

Methodology

Data were obtained from the FAERS database, focusing on reports where Genvoya® was the primary suspected drug, and analyzed using disproportionality analysis methods.

Potential Biases

The geographic distribution of reports may lead to a systematic bias, as most data come from developed countries.

Limitations

The study has limitations including reporting biases and incomplete information, and it is restricted to a single drug analysis.

Participant Demographics

The majority of reports were from male patients (74.33%) aged 18-65 years.

Digital Object Identifier (DOI)

10.3389/fphar.2024.1439781

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication